buserelin has been researched along with Experimental Mammary Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sandow, J; Stoeckemann, K | 1 |
| Andoh, T; Horiguchi, J; Iino, Y; Koibuchi, Y; Maemura, M; Matsumoto, H; Morishita, Y; Sugamata, N; Takei, H; Yokoe, T | 1 |
| Giat, J; Levy, J; Segal-Abramson, T; Sharoni, Y | 1 |
| Kéri, G; Nicholson, RI | 1 |
| Bakker, GH; de Jong, FH; Foekens, JA; Klijn, JG; Lamberts, SW; Portengen, H; Reubi, JC; Setyono-Han, B; van Putten, WL | 1 |
| Cortese, P; Defabiani, E; Giai, M; Sismondi, P | 1 |
| Bakker, GH; De Jong, FH; Foekens, JA; Klijn, JG; Portengen, H; Setyono-Han, B | 1 |
| Furr, BJ | 1 |
| Fraser, HM; Geisthövel, F; Sandow, J | 1 |
| Bakker, GH; de Jong, FH; Henkelman, MS; Klijn, JG; Lamberts, SW; Setyono-Han, B; van der Schoot, P | 1 |
| Furr, BJ; Hutchinson, FG | 2 |
2 review(s) available for buserelin and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
[Zoladex in the treatment of mammary carcinoma].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Buserelin; Goserelin; Humans; Mammary Neoplasms, Experimental | 1990 |
Pharmacology and experimental basis of therapy with LHRH agonists in women.
Topics: Administration, Intranasal; Animals; Buserelin; Endometriosis; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Kinetics; Mammary Neoplasms, Experimental; Ovary; Receptors, LHRH | 1986 |
10 other study(ies) available for buserelin and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Amino Acid Sequence; Animals; Antineoplastic Agents; Buserelin; Delayed-Action Preparations; Female; Gonadotropin-Releasing Hormone; Mammary Neoplasms, Experimental; Molecular Sequence Data; Oligopeptides; Rats; Rats, Sprague-Dawley | 1993 |
The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Implants; Estradiol; Female; Gonadotropin-Releasing Hormone; Mammary Neoplasms, Experimental; Organ Size; Ovariectomy; Rats; Rats, Sprague-Dawley; Uterus | 1999 |
Guanine nucleotide modulation of high affinity gonadotropin-releasing hormone receptors in rat mammary tumors.
Topics: Animals; Binding, Competitive; Buserelin; GTP-Binding Proteins; Guanine Nucleotides; Guanosine 5'-O-(3-Thiotriphosphate); Guanosine Triphosphate; Kinetics; Mammary Neoplasms, Experimental; Rats; Receptors, LHRH | 1992 |
Antitumour activity of folligen, a novel gonadotropin-releasing hormone analogue against DMBA-induced tumours in the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Buserelin; Estradiol; Female; Gonadotropin-Releasing Hormone; Goserelin; Mammary Neoplasms, Experimental; Organ Size; Progesterone; Rats; Rats, Inbred Strains; Time Factors; Uterus | 1992 |
The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Buserelin; Drug Screening Assays, Antitumor; Female; Mammary Neoplasms, Experimental; Octreotide; Pituitary Hormones, Anterior; Rats; Rats, Inbred Strains; Receptors, Neurotransmitter; Receptors, Somatostatin; Receptors, Steroid | 1990 |
Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cytosol; Drug Implants; Estrenes; Female; Follicle Stimulating Hormone; Goserelin; Injections, Subcutaneous; Luteinizing Hormone; Mammary Neoplasms, Experimental; Mifepristone; Progestins; Rats; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1989 |
Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
Topics: Animals; Buserelin; Female; Goserelin; Male; Mammary Neoplasms, Experimental; Prostatic Neoplasms; Rats | 1989 |
Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Topics: Animals; Body Weight; Buserelin; Combined Modality Therapy; Estrenes; Female; Follicle Stimulating Hormone; Luteinizing Hormone; Mammary Neoplasms, Experimental; Megestrol; Megestrol Acetate; Mifepristone; Ovariectomy; Rats; Rats, Inbred Strains; Receptors, Estrogen; Receptors, Progesterone | 1987 |
Biodegradable polymers for the sustained release of peptides.
Topics: Animals; Biodegradation, Environmental; Buserelin; Cell Division; Delayed-Action Preparations; Female; Goserelin; Mammary Neoplasms, Experimental; Peptides; Polymers; Rats | 1985 |
Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
Topics: Animals; Buserelin; Delayed-Action Preparations; Female; Goserelin; Male; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Rats | 1985 |